Vinva Investment Management Ltd Purchases Shares of 28,342 Grifols, S.A. $GRFS

Vinva Investment Management Ltd bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,342 shares of the biotechnology company’s stock, valued at approximately $256,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. acquired a new position in shares of Grifols in the 2nd quarter valued at about $414,000. Campbell & CO Investment Adviser LLC grew its position in Grifols by 516.4% during the second quarter. Campbell & CO Investment Adviser LLC now owns 109,464 shares of the biotechnology company’s stock valued at $990,000 after purchasing an additional 91,706 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Grifols by 4.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 286,192 shares of the biotechnology company’s stock valued at $2,587,000 after buying an additional 11,499 shares during the period. Vident Advisory LLC lifted its position in Grifols by 134.5% in the 1st quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock worth $495,000 after buying an additional 39,902 shares in the last quarter. Finally, Groupe la Francaise acquired a new stake in shares of Grifols during the 1st quarter valued at $1,699,000.

Grifols Trading Up 0.8%

Shares of GRFS opened at $8.85 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64. The company has a market cap of $6.08 billion, a price-to-earnings ratio of 46.58, a PEG ratio of 0.32 and a beta of 0.69. The stock has a fifty day moving average price of $9.24 and a two-hundred day moving average price of $9.37. Grifols, S.A. has a 52-week low of $6.19 and a 52-week high of $11.14.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Zacks Research downgraded shares of Grifols from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.30.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.